Wells Fargo & Company Scynexis Inc Transaction History

Wells Fargo & Company

$434 Billion
Q3 2024

A detailed history of Wells Fargo & Company transactions in Scynexis Inc stock. As of the latest transaction made, Wells Fargo & Company holds 5,880 shares of SCYX stock, worth $5,938. This represents 0.0% of its overall portfolio holdings.

Number of Shares

5,880

Previous 8,180 28.12%

Holding current value

$5,938

Previous $16,000 50.0%

% of portfolio

0.0%

Previous 0.0%

15 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 13, 2024	SELL	$1.27 - $2.23 $2,921 - $5,129	-2,300 Reduced 28.12%	5,880 $8,000
Q2 2024 Aug 13, 2024	BUY	$1.4 - $2.77 $2,849 - $5,636	2,035 Added 33.12%	8,180 $16,000
Q1 2024 May 10, 2024	BUY	$1.39 - $2.21 $6 - $11	5 Added 0.08%	6,145 $9,000
Q4 2023 Feb 09, 2024	BUY	$1.56 - $2.24 $28 - $40	18 Added 0.29%	6,140 $13,000
Q2 2023 Aug 15, 2023	SELL	$2.38 - $3.67 $1,918 - $2,958	-806 Reduced 11.63%	6,122 $18,000
Q1 2023 May 12, 2023	BUY	$1.15 - $3.0 $3 - $9	3 Added 0.04%	6,928 $20,000
Q4 2022 Feb 13, 2023	BUY	$1.46 - $2.94 $8 - $17	6 Added 0.09%	6,925 $10,000
Q3 2022 Nov 14, 2022	SELL	$1.83 - $2.93 $7 - $11	-4 Reduced 0.06%	6,919 $16,000
Q2 2022 Aug 12, 2022	BUY	$1.77 - $3.87 $116 - $255	66 Added 0.96%	6,923 $12,000
Q4 2021 Feb 14, 2022	BUY	$4.94 - $7.69 $93 - $146	19 Added 0.28%	6,857 $42,000
Q3 2021 Nov 15, 2021	BUY	$5.3 - $7.89 $4,425 - $6,588	835 Added 13.91%	6,838 $37,000
Q2 2021 Aug 16, 2021	BUY	$6.5 - $9.97 $45 - $69	7 Added 0.12%	6,003 $44,000
Q1 2021 May 13, 2021	BUY	$6.93 - $9.63 $346 - $481	50 Added 0.84%	5,996 $48,000
Q4 2020 Feb 09, 2021	BUY	$4.28 - $7.87 $25,209 - $46,354	5,890 Added 10517.86%	5,946 $46,000
Q3 2020 Nov 05, 2020	BUY	$4.37 - $7.48 $244 - $418	56 New	56 $0

Others Institutions Holding SCYX

# of Institutions

Shares Held

13.7M

Call Options Held

21.9K

Put Options Held

2.6K

View Full List

About SCYNEXIS INC

Ticker SCYX
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 32,651,800
Market Cap $33M
Description
SCYNEXIS, Inc., a biotechnology company, develops products for the treatment fungal infections in the United States. It offers BREXAFEMME (ibrexafungerp tablets) for the treatment of vulvovaginal candidiasis (VVC). The company is developing its lead product candidate, Ibrexafungerp, as a novel oral and intravenous drug for the treatment of vario...

More about SCYX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Wells Fargo & Company, based on Form 13F filings with the SEC.

News

Stay updated on Wells Fargo & Company with notifications on news.

Account

Wells Fargo & Company Scynexis Inc Transaction History